Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721124 | 0.81 | ACHE (0.38) | XDHUSP2SMN1; SMN2 | |
| SCHEMBL7649147 | 0.80 | NFE2L2 (0.38) | FFAR1FFAR4MAOBUSP2 | |
| SCHEMBL392605 | 0.80 | PTGDR2 (0.39) | PTGDR2FFAR1FFAR4XDH | |
| SCHEMBL2291084 | 0.79 | NPC1 (0.37) | PTGDR2XDHKCNN4SMN1; SMN2 | |
| SCHEMBL546111 | 0.77 | TDP1 (0.38) | KCNN4 | |
| SCHEMBL28867665 | 0.77 | XDH (0.51) | FFAR1FFAR4XDHMAOAMAOB | |
| SCHEMBL29940793 | 0.77 | XDH (0.51) | FFAR1FFAR4XDHMAOAMAOB | |
| SCHEMBL30755347 | 0.75 | FFAR1 (0.47) | FFAR1FFAR4KCNN4SMN1; SMN2 | |
| SCHEMBL4749281 | 0.75 | FFAR1 (0.47) | FFAR1FFAR4KCNN4SMN1; SMN2 | |
| SCHEMBL7931901 | 0.75 | XDH (0.50) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | PTGDR2 1556/4885FFAR1 3811/4885FFAR4 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.